340B Commission
Final Report
Background
Commission Meeting - May 22, 2018
Commission Meeting - June 13, 2018
Meeting Agenda
Meeting Ground Rules
Meeting Consent and Release Form
Meeting Testimony
- Diane Nugent, MD, Professor & Chief of Hematology at CHOC Children's Hospital / UC Irvine Medical School
- Adam J. Fein, PhD, Pembroke Consulting Inc. & Drug Channels Institute
- Rena Conti, PhD, The University of Chicago Medicine
- Jeffrey S. Crowley, O'Neill Institute for National & Global Health Law, Georgetown Law
Background Materials
- Medicare Payment Advisory Commission (MedPAC) - Overview of the 340B Drug Pricing Program
- RAND Corporation - The 340B Prescription Drug Discount Program: Origins, Implementation, and Post-Reform Future
- New England Journal of Medicine - Consequences of the 340B Drug Pricing Program
- New England Journal of Medicine - Discounted Drugs for Needy Patients and Hospitals - Understanding the 340B Debate
- American Hospital Association - Major Methodological Flaws Negate Findings from Recent 340B Study
- Pacific Research Institute - Addressing the Problems of Abuse in the 340B Drug Pricing Program
- Health Affairs - The 340B Drug Discount Program
- Forbes - Reforming the 340B Program Will Lower the Price of Prescription Drugs
- U.S. Department of Health & Human Services Office of Inspector General - State Efforts to Exclude 340B Drugs from Medicaid Managed Care Rebates
- The Liberty Education Forum - 340B Reform White Paper
- Drug Channels Institute - Market Distortions from the 340B Drug Pricing Program
- Impact of the 340B Pharmacy Program on Services and Supports for Persons Served by Hemophilia Treatment Centers in the United States
- A Prescription for Manipulation? Ex Ante Strategic Behavior in the 340B Program
Commission Meeting - July 10, 2018
Meeting Agenda
Meeting Ground Rules
Meeting Consent and Release Form
Meeting Testimony
- Sue Veer, MBA, CMPE, President & CEO, Carolina Health Centers, Inc.
- Fenton Markevich, President & CEO, Rx Strategies
- Peggy Tighe, J.D., Principal, Powers Pyles Sutter & Verville PC
- Jack Geisser, Director, Healthcare Policy, Medicaid, and State Initiatives, Biotechnology Innovation Organization
Background Materials
- Government Accountability Office - DRUG DISCOUNT PROGRAM: Federal Oversight of Compliance at 340B Contract Pharmacies Needs Improvement
- 340B Health - EVALUATING 340B HOSPITAL SAVINGS AND THEIR USE IN SERVING LOW-INCOME AND RURAL PATIENTS: Results from 340B Health’s 2017 Annual Survey
- Polsinelli - 340B Drug Pricing Program Under the Microscope
- BKD National health care Group - PRESCRIPTION FOR 340B SUCCESS IN 2018
- Indiana Hemophilia & Thrombosis Center, Inc. - An Introduction to and Updated Regarding the 340B Federal Drug Discount Program
- National Association of Community Health Centers - NACHC 340B Webinar Series Part 1: Basics of the 340B Drug Pricing Program
- Pharmaceutical Research and Manufacturers of America - 340B 101
- Pharmaceutical Research and Manufacturers of America - ICYMI: Analysis finds higher outpatient drug spending at 340B hospitals
- The Columbus Dispatch - SIDE EFFECTS: AN ONGOING INVESTIGATION ON THE RISING COSTS OF PRESCRIPTION DRUGS
- Sovereign States Drug Consortium - Drug Rebate Program
- Paul Lee - 340B Hospitals Denied Claims Appeals on Drug Payments
Commission Meeting - August 15, 2018
Meeting Agenda
Meeting Ground Rules
Meeting Consent and Release Form
Meeting Testimony
Background Materials
- STAT - Azar makes case for revamping hospital drug discounts - to hospitals defending them
- 340B Health - Evaluating the Impact of Raising the DSH Adjustment Percentage Threshold for 340B Program Eligibility on DSH Hospitals and Their Low-Income Patients
- HealthLeaders - DSH Hospital Participation Could Be Halved Under Congressional Bill
- National Association of Medicaid Directors - Medicaid and the 340B Program: Alignment and Modernization Opportunities
- Health Affairs - The Size of the 340B Program and Its Impact on Manufacturer Revenues